Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis
18 Maio 2021 - 9:00AM
Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage
macrophage reprogramming immunotherapy company targeting diseased
macrophages in patients with sepsis, COVID-19 and solid tumors,
today announced that the Israel Innovation Authority (IIA) selected
Enlivex’s ongoing sepsis clinical program to receive a second
non-dilutive grant of approximately $1.1 million for 2021. To
date, Enlivex has received a total of approximately $6.6 million in
non-dilutive grants from the IIA for clinical trials and product
development, excluding this newly approved grant.
The IIA is an independent, publicly funded agency charged with
fostering the development of industrial R&D within the State of
Israel. It provides non-dilutive grants in the form of
reimbursement for actual expenses pre-approved by the IIA. The
grants become repayable only through royalties from future sales of
products developed with the support of the IIA, and the repayment,
if any, is limited to the original grant amount plus
interest.Enlivex is currently recruiting patients to its Phase IIb
trial of AllocetraTM for the treatment of organ dysfunctions
associated with sepsis.
ABOUT ALLOCETRATM
Enlivex is developing AllocetraTM as a universal,
off-the-shelf cell therapy designed to reprogram macrophages
into their homeostatic state. Diseases such as solid cancers,
sepsis, COVID-19 and many others reprogram macrophages out of their
homeostatic state. These non-homeostatic macrophages contribute
significantly to the severity of the respective diseases. By
restoring macrophage homeostasis, AllocetraTM has the potential to
provide a novel immunotherapeutic mechanism of action for
life-threatening clinical indications that are defined as “unmet
medical needs”, as a stand-alone therapy or in combination with
leading therapeutic agents.
ABOUT ENLIVEX Enlivex is a clinical stage
immunotherapy company developing AllocetraTM, a universal,
off-the-shelf cell therapy designed to reprogram macrophages
into their homeostatic state. Resetting non-homeostatic macrophages
into their homeostatic state is critical for immune system
rebalancing and resolution of life-threatening conditions. For more
information, visit http://www.enlivex.com.
Safe Harbor Statement: This press release contains
forward-looking statements, which may be identified by words such
as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,”
“believes,” “should,” “would”, “could,” “intends,” “estimates,”
“suggests,” “has the potential to” and other words of similar
meaning, including statements regarding expected cash balances,
market opportunities for the results of current clinical studies
and preclinical experiments, the effectiveness of, and market
opportunities for, ALLOCETRATM programs. All such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Investors are cautioned that forward-looking statements
involve risks and uncertainties that may affect Enlivex’s business
and prospects, including the risks that Enlivex may not succeed in
generating any revenues or developing any commercial products; that
the products in development may fail, may not achieve the expected
results or effectiveness and/or may not generate data that would
support the approval or marketing of these products for the
indications being studied or for other indications; that ongoing
studies may not continue to show substantial or any activity; and
other risks and uncertainties that may cause results to differ
materially from those set forth in the forward-looking statements.
The results of clinical trials in humans may produce results that
differ significantly from the results of clinical and other trials
in animals. The results of early-stage trials may differ
significantly from the results of more developed, later-stage
trials. The development of any products using the
ALLOCETRATM product line could also be affected by a number of
other factors, including unexpected safety, efficacy or
manufacturing issues, additional time requirements for data
analyses and decision making, the impact of pharmaceutical industry
regulation, the impact of competitive products and pricing and the
impact of patents and other proprietary rights held by competitors
and other third parties. In addition to the risk factors
described above, investors should consider the economic,
competitive, governmental, technological and other factors
discussed in Enlivex’s filings with the Securities and Exchange
Commission, including in the Company’s most recent Annual Report on
Form 20-F filed with the Securities and Exchange Commission.
The forward-looking statements contained in this press release
speak only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements,
except as required under applicable law.
ENLIVEX CONTACT:
Shachar Shlosberger, CFO
Enlivex Therapeutics,
Ltd.
shachar@enlivexpharm.com
Enlivex Therapeutics (NASDAQ:ENLV)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024